- Investor Overview
- Stock Information
- Presentations & Events
- Corporate Governance
- SEC Filings
- Investor FAQs
- Contact Investor Relations
Jackie Marcus or Chris Hodges
Alpha IR Group
Phone: (312) 445-2870
|View printer-friendly version|
|Insys Therapeutics, Inc. Releases Statement on Its Ongoing Mission|
Insys intends to play a meaningful role in providing solutions to address the opioid epidemic by developing innovative products. These potential product solutions include cannabidiol (a novel, non-opioid) for the treatment of opioid dependence, cannabidiol for the treatment of pain and naloxone nasal spray for the treatment of opioid overdose, while continuing to fulfill our mission to improve the quality of patient care in additional areas such as emergency allergic reactions, rare pediatric epilepsies and rare genetic diseases.
Insys has committed significant resources to these efforts including seeking guidance and input from nearly 30 researchers across the country and has ongoing collaborations with leading academic institutions.
“We remain committed to cultivating a culture of trust, transparency and ethical behavior while executing against our mission of improving the quality of care for patients in need,” said
“The Company continues to demonstrate its commitment to patients by investing over 30% of 2016 revenue in R&D programs and is on track to invest over 40% in R&D in 2017,” concluded Motahari.
SUBSYS® and SYNDROS™ are trademarks of
This press release contains forward-looking statements including regarding our (i) belief that the Company will invest 40% of its revenue in R&D in 2017, (ii) belief that the Company has the potential to benefit patients in areas of unmet medical needs, (iii) intentions to play a meaningful role in providing solutions to address the opioid epidemic by developing innovative products and to fulfill our mission to improve the quality of patient cares and (iv) belief that SYNDROS has distinct advantages over the current formulation of dronabinol in soft gel capsule. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to risk factors described in our filings with the
NOTE: All trademarks and registered trademarks are the property of their respective owners.